Patents by Inventor Patricia D. Lawman
Patricia D. Lawman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230270860Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.Type: ApplicationFiled: December 1, 2022Publication date: August 31, 2023Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Publication number: 20230183690Abstract: Chimeric expression constructs encoding an immunogenic polypeptide fused to a lactadherin domain are described. The compositions are useful for delivery of antigens to different cells, including cancer cells.Type: ApplicationFiled: November 15, 2022Publication date: June 15, 2023Inventors: EVREN ALICI, MICHAEL J. SHAMBLOTT, MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN
-
Publication number: 20200317764Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. Codon modification of the mRNA can optimize expression of an immunogenic polypeptide in cancer cells.Type: ApplicationFiled: May 8, 2020Publication date: October 8, 2020Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Patent number: 10751400Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: August 26, 2019Date of Patent: August 25, 2020Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Patent number: 10682401Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 1, 2017Date of Patent: June 16, 2020Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous, Michael J. Shamblott
-
Publication number: 20200000901Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: August 26, 2019Publication date: January 2, 2020Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA, MEGHAN GENTILINI
-
Patent number: 10391158Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: December 11, 2017Date of Patent: August 27, 2019Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Publication number: 20180085448Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: December 11, 2017Publication date: March 29, 2018Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya, Meghan Gentilini
-
Patent number: 9839680Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: January 30, 2017Date of Patent: December 12, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya
-
Publication number: 20170232090Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: ApplicationFiled: May 1, 2017Publication date: August 17, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS, MICHAEL J. SHAMBLOTT
-
Publication number: 20170136109Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: January 30, 2017Publication date: May 18, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA
-
Patent number: 9636388Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: GrantFiled: May 19, 2016Date of Patent: May 2, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Meghan Gentilini, Vijay Ramiya, Marina Victor Abdelmaseeh Bastawrous
-
Publication number: 20170042993Abstract: Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro.Type: ApplicationFiled: May 19, 2016Publication date: February 16, 2017Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, MEGHAN GENTILINI, VIJAY RAMIYA, MARINA VICTOR ABDELMASEEH BASTAWROUS
-
Patent number: 9555088Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: GrantFiled: March 4, 2015Date of Patent: January 31, 2017Assignee: MORPHOGENESIS, INC.Inventors: Michael J. P. Lawman, Patricia D. Lawman, Vijay Ramiya
-
Publication number: 20160361400Abstract: Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.Type: ApplicationFiled: March 4, 2015Publication date: December 15, 2016Inventors: MICHAEL J. P. LAWMAN, PATRICIA D. LAWMAN, VIJAY RAMIYA
-
Patent number: 8030069Abstract: The subject invention provides new materials and methods for the efficient isolation and purification of stem cells. Specifically, conductive immunopolymers with stem cell specific antibodies can be used to remove stem cells from biological fluids.Type: GrantFiled: April 24, 2009Date of Patent: October 4, 2011Assignee: Morphogenesis, Inc.Inventors: Michael J. P. Lawman, Patricia D. Lawman
-
Patent number: 7348015Abstract: Disclosed are methods for treating cancers, particularly tumorigenic types. Cancer cells are modified to express highly immunogenic antigens so that the cells will generate a defensive response in a mammal that exhibits the cancer or is predisposed to cancer and prevent or ameliorate proliferation of cancer cells. The novel cancer cell vaccines are expected to be effective against a wide range of tumors and leukemias.Type: GrantFiled: October 13, 2004Date of Patent: March 25, 2008Assignee: Morphogenesis, Inc.Inventors: Michael J. P. Lawman, Patricia D. Lawman
-
Patent number: 5981708Abstract: The present invention is directed to an autocrine growth factor. In particular, it relates to the production, purification and uses of stem cell proliferation factor (SCPF). In various cell lines, the protein of the invention exists in two forms, a soluble form and a membrane bound form which is detectable on the surface of a small percentage of human bone marrow cells and stimulates the proliferation of these cells. Therefore, SCPF may have a wide range of applications including but not limited to augmenting the growth of hematopoietic stem cells. Further, removal of the protein by an antibody may be useful in controlling tumor cell growth.Type: GrantFiled: July 8, 1997Date of Patent: November 9, 1999Assignee: University of FloridaInventors: Michael J. P. Lawman, Patricia D. Lawman, Nancy D. Denslow
-
Patent number: 5650299Abstract: The present invention is directed to an autocrine growth factor. In particular, it relates to the production, purification and uses of stem cell proliferation factor (SCPF). In various cell lines, the protein of the invention exists in two forms, a soluble form and a membrane bound form which is detectable on the surface of a small percentage of human bone marrow cells and stimulates the proliferation of these cells. Therefore, SCPF may have a wide range of applications including but not limited to augmenting the growth of hematopoietic stem cells. Further, removal of the protein by an antibody may be useful in controlling tumor cell growth.Type: GrantFiled: October 6, 1994Date of Patent: July 22, 1997Assignee: The University of FloridaInventors: Michael J. P. Lawman, Patricia D. Lawman, Nancy D. Denslow